GC
RVMD icon

Guggenheim Capital’s Revolution Medicines RVMD Stock Holding History

Guggenheim Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.96M Sell
26,474
-5,385
-17% -$787K 0.03% 450
2026
Q1 		$3.1M Buy
31,859
+1,877
+6% +$190K 0.02% 571
2025
Q4 		$2.39M Sell
29,982
-391
-1% -$25.6K 0.02% 623
2025
Q3 		$1.42M Sell
30,373
-3,290
-10% -$129K 0.01% 804
2025
Q2 		$1.24M Sell
33,663
-2,984
-8% -$115K 0.01% 810
2025
Q1 		$1.3M Buy
36,647
+1,686
+5% +$68.4K 0.01% 782
2024
Q4 		$1.53M Sell
34,961
-4,392
-11% -$222K 0.01% 744
2024
Q3 		$1.78M Sell
39,353
-1,261
-3% -$54.9K 0.01% 855
2024
Q2 		$1.58M Sell
40,614
-7,976
-16% -$298K 0.01% 903
2024
Q1 		$1.57M Sell
48,590
-3,057
-6% -$90.6K 0.01% 989
2023
Q4 		$1.48M Buy
+51,647
New +$1.24M 0.01% 977

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Guggenheim Capital's RVMD Position: Q2 2026 in Review

Guggenheim Capital reduced its Revolution Medicines (RVMD) stake by 17% in Q2 2026, selling an estimated $787K and leaving 26,474 shares worth $4.96M. The position accounts for 0.03% of the portfolio, ranked #450.

Guggenheim Capital first reported a position in RVMD in Q4 2023 and has held it in 11 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Guggenheim Capital held 26,474 shares of Revolution Medicines worth $4.96M as of Q2 2026.
  • Guggenheim Capital sold 5,385 Revolution Medicines shares in Q2 2026, an estimated $787K.
  • Revolution Medicines made up 0.03% of Guggenheim Capital's portfolio in Q2 2026, its #450 holding.
  • Guggenheim Capital first reported a position in Revolution Medicines in Q4 2023 and has held it in 11 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.